(Q46236663)

English

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial

scientific article published in November 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial (English)

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Sucha Nand

1

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

John Godwin

2

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

Scott Smith

3

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

Kevin Barton

4

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

Laura Michaelis

5

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

Serhan Alkan

6

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

Ranjitha Veerappan

7

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

Karen Rychlik

8

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

Eliza Germano

9

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

Patrick Stiff

10

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

publication date

1 November 2008

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

Leukemia & Lymphoma

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

49

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

11

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

2141-2147

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

Age and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802451254

21 January 2018

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802451254

21 January 2018

Drug resistance mechanisms in acute leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802451254

21 January 2018

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1080%2F10428190802451254

21 January 2018

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1080%2F10428190802451254

21 January 2018

A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802451254

21 January 2018

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

1 reference

https://api.crossref.org/works/10.1080%2F10428190802451254

21 January 2018

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

1 reference

https://api.crossref.org/works/10.1080%2F10428190802451254

21 January 2018

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

1 reference

https://api.crossref.org/works/10.1080%2F10428190802451254

21 January 2018

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190802451254

21 January 2018

High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1080%2F10428190802451254

21 January 2018

Identifiers

10.1080/10428190802451254

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19021057

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46236663&oldid=2101758215"